Search Press releases Keywords From To 12 Feb 2025 BIMZELX[®]▼(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in hidradenitis suppurativa (HS) Read More 31 Jan 2025 RYSTIGGO[®]▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods Read More 15 Jan 2025 UCB showcases decade of growth and Patient Value Strategy driving differentiated innovation Read More 9 Jan 2025 UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform Read More 2 Jan 2025 Transparency notification Wellington Read More 16 Dec 2024 Findings from minzasolmin proof-of-concept ORCHESTRA study shape next steps in UCB Parkinson’s research program Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 1 of 64 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
